Cargando…

Correction to: Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma

Detalles Bibliográficos
Autores principales:	Yu, Bo, Liu, Delong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7273652/ https://www.ncbi.nlm.nih.gov/pubmed/32498692 http://dx.doi.org/10.1186/s13045-020-00902-5

Ejemplares similares

Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma
por: Yu, Bo, et al.
Publicado: (2019)

Correction to: Corneal Epithelial Findings in Patients with Multiple Myeloma Treated with Antibody–Drug Conjugate Belantamab Mafodotin in the Pivotal, Randomized, DREAMM-2 Study
por: Farooq, Asim V., et al.
Publicado: (2020)

Gemtuzumab ozogamicin and novel antibody-drug conjugates in clinical trials for acute myeloid leukemia
por: Yu, Bo, et al.
Publicado: (2019)

Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma
por: Radocha, Jakub, et al.
Publicado: (2021)

Correction to: Antibody–Drug Conjugate Revolution in Breast Cancer: The Road Ahead
por: Grinda, Thomas, et al.
Publicado: (2023)

Targeting BCMA in Multiple Myeloma: Advances in Antibody-Drug Conjugate Therapy
por: Xing, Lijie, et al.
Publicado: (2023)

Emerging Role of Antibody-Drug Conjugates and Bispecific Antibodies for the Treatment of Multiple Myeloma
por: Tai, Waqqas, et al.
Publicado: (2022)

Correction: Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond
por: Chim, C. S., et al.
Publicado: (2019)

Correction: Inhibition of thioredoxin 1 leads to apoptosis in drug-resistant multiple myeloma
por: Raninga, Prahlad V., et al.
Publicado: (2021)

Antibody-drug conjugate therapies in multiple myeloma—what’s next on the horizon?
por: Hartley-Brown, Monique, et al.
Publicado: (2022)

Antibody–Drug Conjugates for Multiple Myeloma: Just the Beginning, or the Beginning of the End?
por: Ray, Upasana, et al.
Publicado: (2023)

Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia
por: Liu, Delong, et al.
Publicado: (2019)

Drug Conjugated and Bispecific Antibodies for Multiple Myeloma: Improving Immunotherapies off the Shelf
por: Barilà, Gregorio, et al.
Publicado: (2021)

Recent updates on CAR T clinical trials for multiple myeloma
por: Lin, Quande, et al.
Publicado: (2019)

Correction: Refinement of 1p36 Alterations Not Involving PRDM16 in Myeloid and Lymphoid Malignancies
por: Duhoux, Francois P., et al.
Publicado: (2011)

Correction: Mehrling, T.; et al. Challenges in Optimising the Successful Construction of Antibody Drug Conjugates in Cancer Therapy. Antibodies 2018, 7, 11
por: Mehrling, Thomas, et al.
Publicado: (2018)

Correction: Experimental African trypanosome infection suppresses the development of multiple myeloma in mice by inducing intrinsic apoptosis of malignant plasma cells
por: De Beule, Nathan, et al.
Publicado: (2018)

BCMA-targeted immunotherapy for multiple myeloma
por: Yu, Bo, et al.
Publicado: (2020)

Correction to: Isatuximab: A Review of Its Use in Multiple Myeloma
por: Frampton, James E.
Publicado: (2021)

Correction: Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis
por: McCurdy, Arleigh, et al.
Publicado: (2023)

Correction to: Design considerations of an IL13Rα2 antibody–drug conjugate for difuse intrinsic pontine glioma
por: Lian, Xiaolei, et al.
Publicado: (2021)

Correction Notice: Serologic Responses to COVID-19 Vaccines in Hematological Patients Are Predominantly Impaired in Lymphoid but not in Myeloid Malignancies
Publicado: (2022)

Correction to: Bispecific antibodies and dual-targeting CAR-T cells for multiple myeloma: latest updates from the 2023 ASCO annual meeting
por: Hou, Jiangxue, et al.
Publicado: (2023)

Correction Notice: Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up
Publicado: (2021)

Author Correction: The biological significance of histone modifiers in multiple myeloma: clinical applications
por: Ohguchi, Hiroto, et al.
Publicado: (2021)

Author Correction to: T-lymphoid progenitor-based immunotherapies: clinical perspectives for one and all
por: Gaudeaux, P., et al.
Publicado: (2022)

Author Correction: Chemically triggered drug release from an antibody-drug conjugate leads to potent antitumour activity in mice
por: Rossin, Raffaella, et al.
Publicado: (2019)

Targeting CD74 in multiple myeloma with the novel, site-specific antibody-drug conjugate STRO-001
por: Abrahams, Cristina L., et al.
Publicado: (2018)

Correction to: Upregulation of FOXM1 leads to diminished drug sensitivity in myeloma
por: Gu, Chunyan, et al.
Publicado: (2019)

Correction: PRMT5 regulates cell pyroptosis by silencing CASP1 in multiple myeloma
por: Xia, Tian, et al.
Publicado: (2021)

Correction: Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trials
Publicado: (2021)

Correction: Translational Modeling Predicts Efficacious Therapeutic Dosing Range of Teclistamab for Multiple Myeloma
por: Girgis, Suzette, et al.
Publicado: (2022)

Correction: Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*
por: Goldenberg, David M., et al.
Publicado: (2020)

Correction: Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma
por: Kurata, Keiji, et al.
Publicado: (2023)

P836: ANTIBODY-DRUG CONJUGATES AS POTENTIAL CAR-T CELL SPECIFIC OFF-SWITCH IN MULTIPLE MYELOMA
por: Bielowski, Anna, et al.
Publicado: (2023)

Melflufen: A Peptide–Drug Conjugate for the Treatment of Multiple Myeloma
por: Mateos, María-Victoria, et al.
Publicado: (2020)

Correction: Adipocytes secreted leptin is a pro-tumor factor for survival of multiple myeloma under chemotherapy
por: Yu, Wen, et al.
Publicado: (2023)

Correction: Large-scale real-life analysis of survival and usage of therapies in multiple myeloma
por: Lopez-Muñoz, N., et al.
Publicado: (2023)

Correction to: The CXCL12gamma chemokine immobilized by heparan sulfate on stromal niche cells controls adhesion and mediates drug resistance in multiple myeloma
por: Ren, Zemin, et al.
Publicado: (2021)

Correction: Clinical evidence for immune-based strategies in early-line multiple myeloma: current challenges in decision-making for subsequent therapy
por: Raje, Noopur, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1nv9isq8cmtakuojl8kl194l9e